AbbVie (ABBV) Gains from Investment Securities (2012 - 2026)
AbbVie (ABBV) reported Gains from Investment Securities of $266.0 million for Q1 2026, up 800.0% year-over-year from $29.6 million in Q1 2025, and up 106.53% on a QoQ basis from -$4.1 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Gains from Investment Securities data on file, last reported at $266.0 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 800.0% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.0 million (down 90.01% YoY) and the FY2025 annual result came in at $3.0 million, down 99.92% from the prior year.
- Gains from Investment Securities improved to $266.0 million in Q1 2026 per ABBV's latest filing, from -$4.1 billion in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.5 billion in Q4 2023 and bottomed at -$4.1 billion in Q4 2025.
- The 5-year median for Gains from Investment Securities is $303.0 million (2024), against an average of $600.7 million.
- The widest annual swing landed in 2023, when Gains from Investment Securities plunged 1087.79%; it then jumped 1301.0% in 2025.
- Tracing ABBV's Gains from Investment Securities over 5 years: stood at $86.0 million in 2022, then soared by 5083.72% to $4.5 billion in 2023, then sank by 42.33% to $2.6 billion in 2024, then slumped by 258.42% to -$4.1 billion in 2025, then surged by 106.53% to $266.0 million in 2026.
- Per Business Quant, the three latest ABBV Gains from Investment Securities figures stand at $266.0 million (Q1 2026), -$4.1 billion (Q4 2025), and $2.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266.00 Mn |
| Mar 31, 2026 | 266.00 Mn |
| Dec 31, 2025 | -4.07 Bn |
| Dec 31, 2025 | -4.07 Bn |
| Sep 30, 2025 | 2.80 Bn |
| Sep 30, 2025 | 2.80 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | -38.00 Mn |
| Mar 31, 2025 | -38.00 Mn |
| Dec 31, 2024 | 2.57 Bn |
| Dec 31, 2024 | 2.57 Bn |
| Sep 30, 2024 | 200.00 Mn |
| Sep 30, 2024 | 200.00 Mn |
| Jun 30, 2024 | 340.00 Mn |
| Jun 30, 2024 | 340.00 Mn |
| Mar 31, 2024 | 660.00 Mn |
| Mar 31, 2024 | 660.00 Mn |
| Dec 31, 2023 | 4.46 Bn |
| Dec 31, 2023 | 4.46 Bn |
| Sep 30, 2023 | 497.00 Mn |
| Sep 30, 2023 | 497.00 Mn |
| Jun 30, 2023 | -1.70 Bn |
| Jun 30, 2023 | -1.70 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Sep 30, 2022 | 86.00 Mn |
| Sep 30, 2022 | 86.00 Mn |
| Jun 30, 2022 | 172.00 Mn |
| Jun 30, 2022 | 172.00 Mn |
| Mar 31, 2022 | 185.00 Mn |
| Mar 31, 2022 | 185.00 Mn |
| Dec 31, 2021 | 1.22 Bn |
| Dec 31, 2021 | 1.22 Bn |
| Sep 30, 2021 | 117.00 Mn |
| Sep 30, 2021 | 117.00 Mn |
| Jun 30, 2021 | 117.00 Mn |
| Jun 30, 2021 | 117.00 Mn |
| Mar 31, 2021 | -49.00 Mn |
| Mar 31, 2021 | -49.00 Mn |
| Dec 31, 2020 | 4.70 Bn |
| Dec 31, 2020 | 4.70 Bn |
| Sep 30, 2020 | -881.00 Mn |
| Sep 30, 2020 | -881.00 Mn |
| Jun 30, 2020 | 869.00 Mn |
| Jun 30, 2020 | 869.00 Mn |
| Mar 31, 2020 | 12.00 Mn |
| Mar 31, 2020 | 12.00 Mn |
| Dec 31, 2019 | 438.00 Mn |
| Dec 31, 2019 | 438.00 Mn |
| Sep 30, 2019 | 182.00 Mn |
| Sep 30, 2019 | 182.00 Mn |
| Jun 30, 2019 | 2.30 Bn |
| Jun 30, 2019 | 2.30 Bn |
| Dec 31, 2018 | -375.00 Mn |
| Dec 31, 2018 | -375.00 Mn |
| Sep 30, 2018 | 95.00 Mn |
| Sep 30, 2018 | 95.00 Mn |
| Jun 30, 2018 | 485.00 Mn |
| Jun 30, 2018 | 485.00 Mn |
| Mar 31, 2018 | -148.00 Mn |
| Mar 31, 2018 | -148.00 Mn |
| Dec 31, 2017 | 79.00 Mn |
| Dec 31, 2017 | 79.00 Mn |
| Sep 30, 2017 | 401.00 Mn |
| Sep 30, 2017 | 401.00 Mn |
| Jun 30, 2017 | 61.00 Mn |
| Jun 30, 2017 | 61.00 Mn |
| Mar 31, 2017 | 84.00 Mn |
| Mar 31, 2017 | 84.00 Mn |
| Dec 31, 2016 | 85.00 Mn |
| Dec 31, 2016 | 85.00 Mn |
| Sep 30, 2016 | 104.00 Mn |
| Sep 30, 2016 | 104.00 Mn |
| Jun 30, 2016 | 94.00 Mn |
| Jun 30, 2016 | 94.00 Mn |
| Mar 31, 2016 | 298.00 Mn |
| Mar 31, 2016 | 298.00 Mn |
| Dec 31, 2015 | -794.00 Mn |
| Dec 31, 2015 | -794.00 Mn |
| Sep 30, 2015 | 5.86 Mn |
| Sep 30, 2015 | 5.86 Mn |
| Jun 30, 2015 | 25.44 Mn |
| Jun 30, 2015 | 25.44 Mn |
| Mar 31, 2015 | 27.10 Mn |
| Mar 31, 2015 | 27.10 Mn |
| Dec 31, 2014 | -572.00 Mn |
| Dec 31, 2014 | -572.00 Mn |
| Sep 30, 2014 | 30.98 Mn |
| Sep 30, 2014 | 30.98 Mn |
| Jun 30, 2014 | 32.34 Mn |
| Jun 30, 2014 | 32.34 Mn |
| Mar 31, 2014 | 47.00 Mn |
| Mar 31, 2014 | 47.00 Mn |
| Dec 31, 2013 | 96.00 Mn |
| Dec 31, 2013 | 96.00 Mn |
| Sep 30, 2013 | 41.00 Mn |
| Sep 30, 2013 | 41.00 Mn |
| Jun 30, 2013 | 6.07 Mn |
| Jun 30, 2013 | 6.07 Mn |
| Mar 31, 2013 | -14.00 Mn |
| Mar 31, 2013 | -14.00 Mn |
| Dec 31, 2012 | 94.00 Mn |
| Dec 31, 2012 | 94.00 Mn |
| Sep 30, 2012 | -12.00 Mn |
| Sep 30, 2012 | -12.00 Mn |
| Jun 30, 2012 | -14.00 Mn |
| Jun 30, 2012 | -14.00 Mn |
| Mar 31, 2012 | -12.00 Mn |
| Mar 31, 2012 | -12.00 Mn |